The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Insights into the MagnetisMM-4 trial
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, briefly discusses the Phase Ib/II MagnetisMM-4 trial (NCT05090566), which is evaluating elranatamab in combination with other agents for patients with multiple myeloma. Dr Raje explains that this umbrella study aims to investigate the efficacy of various combination approaches with elranatamab, and may further allow researchers to understand mechanisms of resistance to bispecific T-cell engagers (BiTES). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Massachusetts General Hospital: Current Employment; Two Seventy Bio: Research Funding; Research to Practice: Honoraria; Medscape: Honoraria; Amgen: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Celgene: Honoraria; Janssen: Consultancy, Honoraria.
